October 11, 2024 07:17 AM EDTUpdated 08:18 AM
Pharma
FDA+

Ex­clu­sive: PhRMA at­tacks fed­er­al gov­ern­men­t's re­sponse to re­bate mod­el for 340B

Nicole DeFeudis

Editor

The phar­ma in­dus­try’s DC-based lob­by­ing group urged the fed­er­al gov­ern­ment on Fri­day to get on board with al­ter­na­tive mod­els for 340B drug price dis­counts. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sanofi dis­con­tin­ues De­nali-part­nered MS tri­al af­ter Phase 2 fail­ure

Lil­ly fol­lows the trend of new AI hires; Pfiz­er fills key UK po­si­tion as ac­tivist hub­bub swells

Ex­clu­sive: How an ac­ci­den­tal email tipped Pfiz­er off to an ac­tivist in­vestor’s plan

Biotech star­tups Up­stream and CAMP4 price Fri­day IPOs

Up­dat­ed: FDA ap­proves Roche's new treat­ment for sub­set of breast can­cer pa­tients

FDA ad­comm sup­ports first po­ten­tial drug for ul­tra-rare, fa­tal Barth syn­drome

A service from the Financial Times